These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12772010)

  • 1. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion.
    Hunt RH
    Can J Gastroenterol; 2003 May; 17(5):339-41. PubMed ID: 12772010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.
    Maetzel A
    Can J Gastroenterol; 2003 May; 17(5):335-8. PubMed ID: 12772009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.
    Scheiman JM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI40-6. PubMed ID: 12086292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
    Peura DA
    Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?
    Laine L
    J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S5-10; discussion S11-4. PubMed ID: 11992743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
    Meyer-Kirchrath J; Schrör K
    Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
    N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
    Fendrick AM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal safety of selective COX-2 inhibitors.
    Hawkey CJ; Skelly MM
    Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications.
    Meagher EA
    Drug Saf; 2003; 26(13):913-24. PubMed ID: 14583067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery.
    Cicconetti A; Bartoli A; Ripari F; Ripari A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Feb; 97(2):139-46. PubMed ID: 14970772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal safety of COX-2 specific inhibitors.
    Hawkey CJ; Jones JI
    Gastroenterol Clin North Am; 2001 Dec; 30(4):921-36. PubMed ID: 11764535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.